Companies will establish offices in proximity to their respective facilities in the U.S. and China.
Merck & Co. and BGI signed a statement of intent to initiate and develop a working relationship. Both parties intend to build infrastructure to support collaboration in areas such as biomarkers, target validation, and drug de-risking and development.
“This statement of intent is an initial step designed to bring together Merck’s expertise in pharmaceutical development with the powerful sequencing and bioinformatics capabilities of BGI,” says Peter S. Kim, president of Merck Research Laboratories.
The companies will explore areas of mutual interest in healthcare research and discovery by leveraging genomic information. The agreement establishes desired principles of cooperation that Merck and BGI could use to develop separate master agreements and projects. This includes setting up of mutual offices in proximity to their respective facilities in the U.S. and China to enable closer collaboration.